Osteoporosis Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Amgen and UCB, EnteraBio, Rani Therapeutics, Lactocore, Rani Therapeutics, Jiangsu HengRui Medi

The Key Osteoporosis Companies in the market include - Amgen and UCB, EnteraBio, Rani Therapeutics, Lactocore, Rani Therapeutics, Jiangsu HengRui Medicine, Levolta Pharmaceuticals, Inc., Celltrion, Teva Pharmaceuticals, and others.

DelveInsight's "Osteoporosis Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Osteoporosis, historical and forecasted epidemiology as well as the Osteoporosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Osteoporosis, offering comprehensive insights into the Osteoporosis revenue trends, prevalence, and treatment landscape. The report delves into key Osteoporosis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Osteoporosis therapies. Additionally, we cover the landscape of Osteoporosis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Osteoporosis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Osteoporosis space.

To Know in detail about the Osteoporosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Osteoporosis Market Forecast [https://www.delveinsight.com/sample-request/osteoporosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Osteoporosis Market Report:

*
The Osteoporosis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

*
In March 2025, the FDA approved Fresenius Kabi Biopharma's denosumab biosimilars, Conexxence and Bomyntra (denosumab-bnht), for all indications of the reference products Prolia and Xgeva, expanding access to more affordable treatments for osteoporosis, bone metastases, and other bone-related conditions.

*
In March 2025, Dr. Reddy's Laboratories Ltd. and Alvotech announced that the FDA has accepted a 351(k) Biologic License Application (BLA) submission for AVT03, a proposed biosimilar of Prolia Registered (denosumab) and Xgeva Registered (denosumab), developed by Alvotech.

*
In March 2025, Celltrion announced that the U.S. Food and Drug Administration (FDA) has approved STOBOCLO Registered (CT-P41, denosumab-bmwo) and OSENVELT Registered (CT-P41, denosumab-bmwo), biosimilars referencing PROLIA Registered (denosumab) and XGEVA Registered (denosumab), respectively, for all indications of the reference products.

*
In November 2024, the FDA accepted the biologics license application for HLX14, a denosumab (PROLIA/XGEVA) biosimilar, from Organon and Shanghai Henlius Biotech. Denosumab is FDA-approved for treating postmenopausal women at high fracture risk, those with inadequate responses to other osteoporosis treatments, and patients on long-term corticosteroids.

*
Key Osteoporosis Companies: Amgen and UCB, EnteraBio, Rani Therapeutics, Lactocore, Rani Therapeutics, Jiangsu HengRui Medicine, Levolta Pharmaceuticals, Inc., Celltrion, Teva Pharmaceuticals, and others

*
Key Osteoporosis Therapies: EVENITY (romososzumab), EB613 (PTH 1-34), RT-102, Research programme, RT-102, SHR-1222, VOLT01, CT-P41, TVB-009, and others

*
The Osteoporosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteoporosis pipeline products will significantly revolutionize the Osteoporosis market dynamics.

*
As per the International Osteoporosis Foundation, Osteoporosis affected approximately 5.2% of the total population in the UK, closely aligning with the EU27+2 average of 5.6%. Among individuals aged 50 and above in the UK, it was estimated that 21.9% of women and 6.7% of men had Osteoporosis. Hip fractures are considered the most severe outcome of the disease due to their significant impact on health, mortality, and healthcare costs.

*
A study by Yoshimura et al. (2022) reported that in Japan, the prevalence of lumbar spine (L2-L4) osteoporosis was 13.6% at the initial survey (3.4% in men and 19.2% in women) and dropped significantly to 9.7% at the fourth survey (1.4% in men and 13.9% in women), with the difference being statistically significant (p < 0.01). However, no significant change was observed in the prevalence of femoral neck osteoporosis between the two surveys.

Osteoporosis Overview

Osteoporosis is a medical condition in which bones become weak, brittle, and more prone to fractures due to a loss of bone density and strength. It often develops silently over time and is most common in older adults, especially postmenopausal women. Common fracture sites include the hip, spine, and wrist. The condition can be managed or prevented through calcium and vitamin D intake, regular weight-bearing exercise, and medications that help strengthen bones.

Get a Free sample for the Osteoporosis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/osteoporosis-market [https://www.delveinsight.com/report-store/osteoporosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Osteoporosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Osteoporosis Epidemiology Segmentation:

The Osteoporosis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

*
Total Prevalence of Osteoporosis

*
Prevalent Cases of Osteoporosis by severity

*
Gender-specific Prevalence of Osteoporosis

*
Diagnosed Cases of Episodic and Chronic Osteoporosis

Download the report to understand which factors are driving Osteoporosis epidemiology trends @ Osteoporosis Epidemiology Forecast [https://www.delveinsight.com/sample-request/osteoporosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Osteoporosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Osteoporosis market or expected to get launched during the study period. The analysis covers Osteoporosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Osteoporosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Osteoporosis Therapies and Key Companies

*
EVENITY (romososzumab): Amgen and UCB

*
EB613 (PTH 1-34): EnteraBio

*
RT-102: Rani Therapeutics

*
Research programme: Lactocore

*
RT-102: Rani Therapeutics

*
SHR-1222: Jiangsu HengRui Medicine

*
VOLT01: Levolta Pharmaceuticals, Inc.

*
CT-P41: Celltrion

*
TVB-009: Teva Pharmaceuticals

Discover more about therapies set to grab major Osteoporosis market share @ Osteoporosis Treatment Landscape [https://www.delveinsight.com/sample-request/osteoporosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Osteoporosis Market Drivers

*
Rising geriatric population prone to low bone density, growing investments in research and development, increased focus on development of biosimilars for the treatment of Osteoporosis are some of the important factors that are fueling the Osteoporosis Market.

Osteoporosis Market Barriers

*
However, side effects and complications associated with osteoporosis drugs, patent expiration of osteoporosis drugs and other factors are creating obstacles in the Osteoporosis Market growth.

Scope of the Osteoporosis Market Report

*
Study Period: 2019-2032

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Osteoporosis Companies: Amgen and UCB, EnteraBio, Rani Therapeutics, Lactocore, Rani Therapeutics, Jiangsu HengRui Medicine, Levolta Pharmaceuticals, Inc., Celltrion, Teva Pharmaceuticals, and others

*
Key Osteoporosis Therapies: EVENITY (romososzumab), EB613 (PTH 1-34), RT-102, Research programme, RT-102, SHR-1222, VOLT01, CT-P41, TVB-009, and others

*
Osteoporosis Therapeutic Assessment: Osteoporosis current marketed and Osteoporosis emerging therapies

*
Osteoporosis Market Dynamics: Osteoporosis market drivers and Osteoporosis market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Osteoporosis Unmet Needs, KOL's views, Analyst's views, Osteoporosis Market Access and Reimbursement

To know more about Osteoporosis companies working in the treatment market, visit @ Osteoporosis Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/osteoporosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Osteoporosis Market Report Introduction

2. Executive Summary for Osteoporosis

3. SWOT analysis of Osteoporosis

4. Osteoporosis Patient Share (%) Overview at a Glance

5. Osteoporosis Market Overview at a Glance

6. Osteoporosis Disease Background and Overview

7. Osteoporosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Osteoporosis

9. Osteoporosis Current Treatment and Medical Practices

10. Osteoporosis Unmet Needs

11. Osteoporosis Emerging Therapies

12. Osteoporosis Market Outlook

13. Country-Wise Osteoporosis Market Analysis (2019-2032)

14. Osteoporosis Market Access and Reimbursement of Therapies

15. Osteoporosis Market Drivers

16. Osteoporosis Market Barriers

17. Osteoporosis Appendix

18. Osteoporosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=osteoporosis-market-statistics-expected-to-experience-major-growth-by-2032-according-to-delveinsight-amgen-and-ucb-enterabio-rani-therapeutics-lactocore-rani-therapeutics-jiangsu-hengrui-medi]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.